Key points are not available for this paper at this time.
Design
Review
May support LVH regression as hypertension target beyond BP control; leaves open optimal coronary protection strategies.
The manifestations of cardiac involvement in hypertension include: (1) the development of hypertensive heart disease characterized by left ventricular hypertrophy (LVH), and (2) the consequences of coronary atherosclerosis, as angina pectoris, myocardial infarction, and sudden cardiac death. Whereas the former is directly related to increased blood pressure, the latter are sequelae of atherosclerosis per se, and hypertension acts only as a risk factor in this regard. This can partially explain why antihypertensive treatment is effective in diminishing the incidence of congestive heart failure, which is the final consequence of LVH, but is not very effective in preventing coronary complications. It is generally accepted about LVH that increased arterial pressure is the major stimulus to cardiac hypertrophy in hypertension; however, there are a lot of both quantitative and qualitative events suggesting that other factors beside blood pressure levels can modulate the development of LVH, in particular neurohumoral influences. From a morphological point of view, hypertrophy of the cardiac muscle is defined as an increase in the size of existing myocardial fibers. In most experimental models, myocardial hypertrophy is associated with myosin isoenzymatic changes, consisting in a shift from the faster migrating isoenzyme V! to V 3 , a form that migrates more slowly. However these changes do not occur in all animal species and particularly in humans. In the hypertrophied human ventricle, a decreased ATPase activity of myofibrils was observed, probably related to changes in myosin light chains. Presently the changes in ATPase activity and in ventricular contractility do not still have a clear molecular basis in humans. The main consequences of LVH on myocardial function include: (1) effects on contractility, (2) effects on myocardial response to adrenergic stimulation, (3) effects on diastolic function, and (4) effects on coronary blood flow. As LVH has been demonstrated to be associated with a high incidence of cardiovascular morbidity and mortality, the therapeutic goal for treating hypertension is not only to normalize blood pressure but also to prevent or reverse cardiac damage. Am J Hypertens 1989;2:16S-23S
No takes yet. Share an insight, caveat, or question.
Fogari et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: